Figures & data
Figure 1. Different stimulatory activity of IL-2/JES6.1 and IL-2/S4B6 immunocomplexes. (A) IL-2/JES6.1 immunocomplexes essentially require high-affinity trimeric IL-2 receptor to be expressed on cell surface. Thus, the utilization of IL-2/JES6.1 immunocomplexes is limited to CD25 expressing cells (left part). On the other hand, intermediate affinity dimeric receptor is sufficient to utilize IL-2/S4B6 immunocomplexes being available for much broader spectrum of immune cells (right part). (B) IL-2/JES6.1 immunocomplexes potently and selectively expand Treg cells while not increasing the number of effectors and thus generally promote tolerance. (C) IL-2/S4B6 immunocomplexes stimulate expansion of effectors much strongly than expansion of Treg cells and thus generally promote immunity.
Figure 2. IL-2 complexed with S4B6 or JES6.1 possesses a potential to be used for therapy of various diseases. IL-2 complexed with S4B6 enormously expands effector immune cells and demonstrates significant potential in cancer immunotherapy and potentiation of vaccination (left part). IL-2 complexed with JES6.1 dramatically expands Treg cells and show promising potential to increase transplantation success rate and to treat auto-immune diseases.
